Shanghai Pharmaceutical (Hunan) Co., Ltd. entered into an agreement to acquire 51% stake in Hunan Runji Pharmaceutical Co., Ltd. from Realcan Pharmaceutical Group Co., Ltd. (SZSE:002589) for CNY 149 million on January 16, 2023. The board of directors of Realcan Pharmaceutical Group approved the transaction. Hunan Runji Pharmaceutical recorded total assets of CNY 812.75 million and net assets of CNY 185.94 million as of September 30, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.68 CNY | -.--% | +11.67% | -18.04% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.04% | 557M | |
+16.03% | 70.59B | |
+2.22% | 25.06B | |
+7.11% | 8.2B | |
-2.98% | 7.92B | |
-20.55% | 7.96B | |
+3.54% | 4.71B | |
+17.12% | 4.32B | |
-1.24% | 4.01B | |
-3.44% | 3.82B |
- Stock Market
- Equities
- 002589 Stock
- News Realcan Pharmaceutical Group Co., Ltd.
- Shanghai Pharmaceutical Co., Ltd. entered into an agreement to acquire 51% stake in Hunan Runji Pharmaceutical Co., Ltd. from Realcan Pharmaceutical Group Co., Ltd. for CNY 149 million